PA-BOOMI
7.5.2024 15:01:27 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, announced today the winners of its 2024 Partner Awards, recognized at the 2024 Boomi Partner Summit held in Denver, Colorado. These awards recognize innovative partners who successfully leverage their Boomi relationship to accelerate business outcomes for customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507194022/en/
Boomi Announces 2024 Partner Award Winners (Graphic: Business Wire)
Winners were selected based on how they utilized the breadth of the Boomi platform to enable creativity and innovation, scope and complexity, and environmental or social impact.
“As frontrunners in the domain of IT and digital advancement, we are delighted to extend our appreciation to our esteemed partners for their invaluable contributions to the success of our mutual customers,” said Dan McAllister, Senior Vice President of Global Alliances and Channels at Boomi. “Their dedication and efforts play a pivotal role in optimizing operational efficiencies and leveraging automation to confront the dynamic challenges of contemporary business landscapes.”
This year’s winners by category include:
- Global Partner of the Year: Infosys Limited
- Americas Partner of the Year: RSM US LLP
- EMEA Partner of the Year: Cognizant Technology Solutions Corporation
- APJ Partner of the Year: Atturra
- OEM Partner of the Year: UKG Inc.
- ISV Partner of the Year: Amazon Web Services (AWS)
- Technology Partner of the Year: Solace Corporation
- Emerging Technology Partner of the Year: Thru Inc.
Boomi offers end-to-end intelligent automation solutions that enable modern, digital organizations to accelerate business outcomes. The company serves more than 20,000 customers, has a worldwide network of approximately 800 partners, and works with the largest hyperscaler cloud service providers.
Boomi has been positioned as a Leader in the Gartner® Magic Quadrant™ for Integration Platform as a Service (iPaaS) for ten consecutive years, has been named a Strong Performer in the Forrester Wave™: Integration Platforms As A Service, Q3 2023, and positioned as a Leader in the IDC MarketScape: Worldwide Cloud Integration Software and Services (iPaaS) 2023 Vendor Assessment. Named one of the Top 100 Software Companies of 2023 by The Software Report, Boomi is also a Gold Stevie® winner in the American Business Awards. In addition, Boomi has been recognized as a Cloud 100 company by CRN and has received the prestigious 5-star rating for three consecutive years in the CRN Partner Program Guide, a definitive list of the most notable programs from industry-leading technology vendors that provide innovative products and flexible services through the IT channel.
To learn more about Boomi’s partner program, or to find a partner from Boomi’s global ecosystem, visit https://boomi.com/partners/.
Additional Resources
- Learn more about the Boomi platform
- Explore the Boomiverse Community
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507194022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom